

# Kenneth A Getz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7452849/kenneth-a-getz-publications-by-year.pdf>

**Version:** 2023-01-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

58  
papers

1,462  
citations

16  
h-index

38  
g-index

63  
ext. papers

1,732  
ext. citations

4.3  
avg, IF

4.61  
L-index

#	Paper	IF	Citations
58	Tufts Center for the Study of Drug Development Employs Broadly Engaged Team Science to Explore the Challenges of Pharmaceutical Research and Development <b>2022</b> , 55-63		
57	Benchmarking Protocol Deviations and Their Variation by Major Disease Categories.. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2022</b> , 1	1.1	
56	Protocol Design Variables Highly Correlated with, and Predictive of, Clinical Trial Performance.. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2022</b> , 56, 333	1.1	0
55	Benchmarking Patient Recruitment and Retention Practices. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2021</b> , 55, 19-32	1.1	2
54	Evaluating the Feasibility and Validity of a New Tool to Assess Organizational Preparedness and Capabilities to Support Patient Engagement in Drug Development. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2021</b> , 55, 1193-1198	1.1	0
53	Guidelines for Reporting Trial Protocols and Completed Trials Modified Due to the COVID-19 Pandemic and Other Extenuating Circumstances: The CONSERVE 2021 Statement. <i>JAMA - Journal of the American Medical Association</i> , <b>2021</b> , 326, 257-265	26.8	24
52	The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research. <i>Lupus Science and Medicine</i> , <b>2021</b> , 8,	4.5	1
51	Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. <i>Clinical Therapeutics</i> , <b>2020</b> , 42, e150-e159	3.4	2
50	Establishing Consensus Understanding of the Barriers to Drug Development in Lupus. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 1159-1165	1.1	2
49	Quantifying Patient Subpopulation Disparities in New Drugs and Biologics Approved Between 2007 and 2017. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 1541-1550	1.1	3
48	Assessing the Scope and Predictors of Intentional Dose Non-adherence in Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 1330-1338	1.1	1
47	Benchmarking the Vendor Qualification Process. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 1349-1358	1.1	
46	US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 404-410	1.1	1
45	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 103-116	1.1	17
44	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2020</b> , 54, 598-604	1.1	1
43	Assessing Patient Participation Burden Based on Protocol Design Characteristics. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2019</b> , 2168479019867284	1.1	5
42	Differences in Clinical Research Perceptions and Experiences by Age Subgroup. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2019</b> , 216847901881472	1.1	

41	Reflections on the Evolution of Patient Engagement in Drug Development. <i>Pharmaceutical Medicine</i> , <b>2019</b> , 33, 179-185	2.2	10
40	US Physician and Nurse Proclivity to Refer Their Patients Into Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2019</b> , 216847901983796	1.1	
39	Measuring the Impact of Patient Engagement and Patient Centricity in Clinical Research and Development. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2019</b> , 216847901881751	1.1	8
38	Evaluating the Completeness of ClinicalTrials.gov. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2019</b> , 53, 307-317	1.1	9
37	Cost Drivers of a Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia Phase 3 Clinical Trial. <i>Clinical Infectious Diseases</i> , <b>2018</b> , 66, 72-80	11.3	11
36	Assessing the Financial Value of Patient Engagement: A Quantitative Approach from CTTI's Patient Groups and Clinical Trials Project. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2018</b> , 52, 220-229	1.1	60
35	New Benchmarks Characterizing Growth in Protocol Design Complexity. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2018</b> , 52, 22-28	1.1	17
34	Global Public Attitudes About Clinical Research and Patient Experiences With Clinical Trials. <i>JAMA Network Open</i> , <b>2018</b> , 1, e182969	10.1	33
33	Trends driving clinical trials into large clinical care settings. <i>Nature Reviews Drug Discovery</i> , <b>2018</b> , 17, 703-704	62	2
32	Baseline Assessment of a Global Clinical Investigator Landscape Poised for Structural Change. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2017</b> , 51, 575-581	1.1	4
31	Examining and Enabling the Role of Health Care Providers as Patient Engagement Facilitators in Clinical Trials. <i>Clinical Therapeutics</i> , <b>2017</b> , 39, 2203-2213	3.4	14
30	Analysis of Review Times for Recent 505(b)(2) Applications. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2017</b> , 51, 651-656	1.1	2
29	The Impact of Protocol Amendments on Clinical Trial Performance and Cost. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2016</b> , 50, 436-441	1.1	24
28	Bridging the Academia/Industry Chasm: Proposed Solutions. <i>Journal of Clinical Pharmacology</i> , <b>2016</b> , 56, 1457-1460	2.8	
27	A Survey of Adverse Event Reporting Practices Among US Healthcare Professionals. <i>Drug Safety</i> , <b>2016</b> , 39, 1117-1127	5	25
26	Quantifying the magnitude and cost of collecting extraneous protocol data. <i>American Journal of Therapeutics</i> , <b>2015</b> , 22, 117-24	0.9	19
25	Establishing Return-on-Investment Expectations for Patient-Centric Initiatives. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2015</b> , 49, 745-749	1.1	14
24	Generational Value Differences Affecting Public Perceptions of and Willingness to Participate in Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2015</b> , 49, 940-946	1.1	5

23	The Impact of Bad Protocols <b>2015</b> , 105-116		1
22	Evaluating AE Reporting of Two Off-Patent Biologics to Inform Future Biosimilar Naming and Reporting Practices. <i>Drug Safety</i> , <b>2015</b> , 38, 687-92	5	2
21	The Impact of Collaborative and Risk-Sharing Innovation Approaches on Clinical and Regulatory Cycle Times. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2014</b> , 48, 482-487	1.1	11
20	Site Characteristics Influencing the Translation of Clinical Research Into Clinical Practice. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2014</b> , 48, 628-634	1.1	
19	Evaluating the completeness and accuracy of MedWatch data. <i>American Journal of Therapeutics</i> , <b>2014</b> , 21, 442-6	0.9	28
18	Taking the pulse of strategic outsourcing relationships. <i>Clinical Therapeutics</i> , <b>2014</b> , 36, 1349-55	3.4	8
17	Therapeutic area variability in the collection of data supporting protocol end points and objectives. <i>Clinical Investigation</i> , <b>2014</b> , 4, 125-130		3
16	Communicating trial results to study volunteers: what does the future hold?. <i>Clinical Investigation</i> , <b>2014</b> , 4, 777-779		1
15	Improving protocol design feasibility to drive drug development economics and performance. <i>International Journal of Environmental Research and Public Health</i> , <b>2014</b> , 11, 5069-80	4.5	26
14	Unfulfilled translation opportunities in industry sponsored clinical trials. <i>Contemporary Clinical Trials</i> , <b>2013</b> , 35, 80-6	2.2	1
13	Impact of In-Pharmacy Education on PatientsTKnowledge and Attitudes About Clinical Trials. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2013</b> , 47, 336-340	1.1	2
12	New Governance Mechanisms to Optimize Protocol Design. <i>Therapeutic Innovation and Regulatory Science</i> , <b>2013</b> , 47, 651-655	1.1	9
11	Meeting the obligation to communicate clinical trial results to study volunteers. <i>Expert Review of Clinical Pharmacology</i> , <b>2012</b> , 5, 149-56	3.7	16
10	Are Pharmacists a Viable Channel for Education about Clinical Trial Participation?. <i>Drug Information Journal</i> , <b>2011</b> , 45, 443-453		2
9	The Promise and Progress of DIA 2011. <i>Drug Information Journal</i> , <b>2011</b> , 45, 119-120		
8	Factors Influencing Investigative Site Willingness and Ability to Participate in Clinical Trials. <i>Drug Information Journal</i> , <b>2011</b> , 45, 377-390		3
7	Measuring the Incidence, Causes, and Repercussions of Protocol Amendments. <i>Drug Information Journal</i> , <b>2011</b> , 45, 265-275		36
6	Variability in Protocol Design Complexity by Phase and Therapeutic Area. <i>Drug Information Journal</i> , <b>2011</b> , 45, 413-420		21

5	Assessing the impact of protocol design changes on clinical trial performance. <i>American Journal of Therapeutics</i> , <b>2008</b> , 15, 450-7	0.9	105
4	Racial disparities among clinical research investigators. <i>American Journal of Therapeutics</i> , <b>2008</b> , 15, 3-11	0.9	29
3	Public and patient usage and expectations for clinical trial registries <b>2006</b> , 47-58		2
2	Central challenges facing the national clinical research enterprise. <i>JAMA - Journal of the American Medical Association</i> , <b>2003</b> , 289, 1278-87	26.8	857
1	The Expanding Outside Clinical Services Contractor Marketplace. <i>Clinical Research and Regulatory Affairs</i> , <b>1997</b> , 14, 191-204		3